Clinical Trial Update: Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating subcutaneous and intravenous Velcade in combination with dexamethasone for Chinese patients with relapsed and refractory multipl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Velcade (bortezomib)
• Velcade (subcutaneous and intravenous) (bortezomib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED